Lantern Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	5.98	5.83	5.02	3.66	1.48	1.15
Research & Development	11.89	8.6	7.57	2.24	0.95	0.57
Operating Expenses	17.88	14.43	12.59	5.91	2.43	1.73
Operating Income	-17.88	-14.43	-12.59	-5.91	-2.43	-1.73
Other Expense / Income	-1.92	-0.17	-0.23	-	-	-
Pretax Income	-15.96	-14.26	-12.36	-5.91	-2.43	-1.73
Net Income	-15.96	-14.26	-12.36	-5.91	-2.43	-1.73
Shares Outstanding (Basic)	11	11	11	4	2	1
Shares Outstanding (Diluted)	11	11	11	4	2	1
Shares Change	-0.08%	-0.50%	153.31%	117.61%	78.64%	-
EPS (Basic)	-1.47	-1.31	-1.13	-1.37	-1.23	-1.56
EPS (Diluted)	-1.47	-1.31	-1.13	-1.37	-1.23	-1.56
Free Cash Flow	-14.37	-12.8	-10.61	-5.67	-2.13	-1.27
Free Cash Flow Per Share	-1.32	-1.18	-0.97	-1.32	-1.08	-1.14
EBITDA	-15.79	-14.11	-12.27	-5.9	-2.43	-1.73
Depreciation & Amortization	0.17	0.15	0.1	0	0	-0
EBIT	-15.96	-14.26	-12.36	-5.91	-2.43	-1.73

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).